Vaccine therapy for malignant melanoma

Ca-A Cancer Journal for Clinicians

Volumn 46, Issue 4, 1996, Pages 225-244

  Morton, Donald L ^a   Barth, Andreas ^a,b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; DACARBAZINE; INTERLEUKIN 2;

ADJUVANT CHEMOTHERAPY; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TUMOR GROWTH;

EID: 0030057341     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.46.4.225     Document Type: Review

References (80)

1. Koh HK: Cutaneous melanoma. N Engl J Med 1991;325:171-182.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
3. Ahmann DL, Creagan ET, Hahn RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989;63:224-227.
4. Anderson CM, Buzaid AC, Legha SS: Systemic treatments for advanced cutaneous melanoma. Oncology 1995;9:1149-1158.
5. Meyers ML: The Anderson/Buzaid/Legha article reviewed [Systemic treatments for advanced cutaneous melanoma]. Oncology 1995;9:1164-1168.
6. Barth A, Wanek LA, Morton DL: Prognostic factors in 1.521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193-201.
7. Sumner WC: Spontaneous regression of melanoma: Report of a case. Cancer 1953;6:1040-1043.
8. Sumner WC, Foraker AG:Spontaneous regression of human melanoma:Clinical and experimental studies. Cancer 1960;13:79-81.
9. Rhodes AR, Weinstock MA, Fitzpatrick TB, et al:Risk factors for cutaneous melanoma:A practical method of recognizing predisposed individuals, JAMA 1987;258:3146-3154.
10. Morton DL, Malmgren RA, Holmes EC, Ketcham AS:Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968;64:233-240.
11. Morton DL, Eilber FR, Malmgren RA, et al:Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-164.
12. Rosenberg SA, Yang JC, Topalian SL, et al:Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
13. Bennett WH:Some peculiarities in the behaviour of certain malignant and innocent growths. Lancet 1899;1:3-7.
14. Goodnight JE, Morton DL:Immunotherapy for malignant disease. Annu Rev Med 1978;29:231-283.
15. Yamamoto S, Yamamoto T, Saxton RE, et al:Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3. J Natl Cancer Inst 1990;82:1757-1760.
16. Morton DL, Ravindranath MH, Irie RF:Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Prog Brain Res 1994;101:251-275.
17. Gupta RK, Morton DL:Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst 1983;70:993-1004.
18. Euhus DM, Gupta RK, Morton DL:Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-254.
19. Gupta RK, Morton DL:Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody:I. Purification and development of a radioimmunoassay. J Natl Cancer Inst 1984;72:67-74.
20. van der Bruggen P, Traversari C, Chomez P, et al:A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-1647.
21. Gaugler B, Van den Eynde B, van der Bruggen P, et al:Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930.
22. Brichard V, Van Pel A, Wolfel T, et al:The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
23. Morioka N, Kikumoto Y, Hoon DS, et al:A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 1994;153:5650-5658.
24. Bakker AB, Schreurs MW, de Boer AJ, et al:Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-1009.
25. Kawakami Y, Eliyahu S, Jennings C, et al:Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
26. Kawakami Y, Eliyahu S, Delgado CH, et al:Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
27. Coulie PG, Brichard V, Van Pel A, et al:A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
28. Vijayasaradhi S, Bouchard B, Houghton AN:The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990;171:1375-1380.
29. Ferrone S:Human tumor-associated antigen mimicry by anti-idiotypic antibodies:Immunogenicity and clinical trials in patients with solid tumors. Ann NY Acad Sci 1993;690:214-224.
30. Mittelman A, Chen ZJ, Yang H, et al:Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23:Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-470.
31. Morton DL, Foshag LJ, Hoon DS, et al:Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
32. Morton DL, Hoon DS, Nizze JA, et al:Polyvalent melanoma, vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 1993;690:120-134.
33. Morton D, Nizze A, Hoon D, et al:Improved survival of advanced Stage IV melanoma following active immunotherapy:Correlation with immune response to melanoma vaccine. Proc Annu Meet Am Soc Clin Oncol 1993;12:391.
34. Tafra L, Dale PS, Wanek LA, et al:Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995;110:119-129.
35. Barth AM, Irie RF, Morton DL:Update on immunotherapy for advanced melanoma. Contemporary Oncol 1994;4:52-60.
36. Spratt JS, Meyer JS, Spratt JA:Rate of growth of human neoplasms:Part II. J Surg Oncol 1996;61:68-83.
37. Hoon DS, Wang Y, Dale PS, et al:Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-2116.
38. Barth A, Hoon DS, Foshag LJ, et al:Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994;54:3342-3345.
39. Morton DL, Nizze JA, Famatiga E, et al:Active immunotherapy with polyvalent melanoma cell vaccine reduces the incidence of secondary brain metastases in stage IV melanoma. Proc Annu Meet Am Assoc Cancer Res 1995;36:A2925.
40. Foshag LJ, Morton DL, Nizze JA, Chawla SP:Response to chemotherapy in melanoma patients after active specific immunotherapy (ASI) with melanoma cell vaccine. Proc Annu Meet Am Soc Clin Oncol 1993;12:A1355.
41. Mitchell MS, Jakowatz J, Harel W, et al:Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994;12:402-411.
42. Mitchell MS, Harel W, Kan-Mitchell J, et al:Active-specific immunotherapy of melanoma with allogeneic cell lysates:Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993;690:153-166.
43. Mitchell MS, Harel W, Kempf RA, et al:Active specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-869.
44. Mitchell MS, Harel W, Groshen S:Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 1992;10:1158-1164.
45. Mitchell MS, Rechtman DJ, Von Eschen KB:A randomized phase III trial of Melacine® versus combination chemotherapy in patients with disseminated melanoma. Can J Infect Dis 1995;6(Suppl C):347C.
46. Mittelman A, Chen ZJ, Kageshita T, et al:Active specific immunotherapy in patients with melanoma:A clinical trial with mouse anti-idiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990;86:2136-2144.
47. Mittelman A, Chen ZJ, Liu CC, et al:Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 1994;54:415-421.
48. Mittelman A, Chen GZJ, Wong GY, et al:Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23:Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995;1:705-713.
49. Berd D, Maguire HC Jr, McCuc P, Mastrangelo MJ:Treatment of metastatic melanoma with an autologous tumor-cell vaccine:Clinical and immunological results in 64 patients. J Clin Oncol 1990;8:1858-1867.
50. Berd D, Maguire HC Jr, Mastrangelo MJ:Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 1993;690:147-152.
51. Sato T, Maguire HC Jr, Mastrangelo MJ, Berd D:Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin Immunol Immunopathol 1995;74:35-43.
52. Morton DL, Wanek L, Nizze JA, et al:Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes:Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491-501.
53. Barth A, Morton DL:Role of adjuvant therapy in melanoma management. Cancer 1995;75:726-734.
54. Kirkwood JM, Strawderman MH, Ernstoff MS, et al:Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma:the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
55. Cascinelli N:Evaluation of efficacy of adjuvant rIFN-α-2a in melanoma patients with regional node metastases. Proc Annu Meet Am Soc Clin Oncol 1995;14:A1296.
56. Creagan ET, Dalton RJ, Ahmann DL, et al:Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-2783.
57. Morton DL, Joseph WL, Ketcham AS, et al:Surgical resection and adjunctive immunotherapy for selected patients with multiple pulmonary metastases. Ann Surg 1973;178:360-366.
58. Morton DL, Eilber FR, Holmes EC, Ramming KP:Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust N Z J Surg 1978;48:49-52.
59. Jones PC, Sze LL, Liu PY, et al:Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981;66:249-254.
60. Hersey P:Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 1992;16:251-260.
61. Hersey P:Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann NY Acad Sci 1993;690:167-177.
62. Bystryn JC, Oratz R, Roses D, et al:Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992;69:1157-1164.
63. Miller K, Abeles G, Oratz R, et al:Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995;75:495-502.
64. Bystryn JC:Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann NY Acad Sci 1993;690:190-203.
65. Berd D, Maguire HC Jr, Hart E, Mastrangelo MJ:Post-surgical adjuvant therapy of melanoma with a dinitrophenyl (DNP)-conjugated vaccine:Prolongation of disease-free and total survival. Proc Annu Meet Am Soc Clin Oncol 1993;12:A1319.
66. Mitchell MS, Spears L, Deans G, Groshen S:Effect of a melanoma lysate vaccine on survival in minimal residual melanoma. Proc Annu Meet Am Assoc Cancer Res 1995;36:A1331.
67. Livingston PO, Wong GY, Adluri S, et al:Improved survival in stage III melanoma patients with GM2 antibodies:A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.
68. Livingston PO, Wong GYC, Adluri S, et al:A randomized trial of adjuvant vaccination with BCG versus BCG plus the melanoma ganglioside GM2 in patients with AJCC stage III melanoma. Ann NY Acad Sci 1993;690:204-213.
69. Wallack MK, Sivanandham M, Balch CM, et al:A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42.
70. Barth A, Hoon DS, Foshag LJ, et al:Enhancement of T-cell response to autologous melanoma following adjuvant immunotherapy with melanoma vaccine. Proc Annu Meet Am Assoc Cancer Res 1994;35:A3060.
71. Salgaller ML, Weber JS, Koenig S, et al:Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 1994;39:105-116.
72. Oratz R, Shapiro R, Chen D, et al:Effect of IL2 liposomes on the immunogenicity of a polyvalent melanoma antigen vaccine. Proc Annu Meet Am Soc Clin Oncol 1994;13:A1350.
73. Nabel GJ, Nabel EG, Yang ZY, et al:Direct gene transfer with DNA-liposome complexes in melanoma:Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11311.
74. Gansbacher B, Zier K, Cronin K, et al:Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood 1992;80:2817-2825.
75. Gansbacher B:Use of IL-2 transduced tumor cells as a vaccine against cancer. Proc Annu Meet Am Assoc Cancer Res 1993;34:583.
76. Osanto S, Brouwenstyn N, Vaessen N, et al:Immunization with interleukin-2 transfected melanoma cells:A phase I-II study in patients with metastatic melanoma. Hum Gene Ther 1993;4:323-330.
77. Osanto S, Browenstijn N, Vaessen N, et al:Gene therapy of metastatic melanoma patients with IL-2 transfected melanoma cells. Proc Annu Meet Am Assoc Cancer Res 1994;35:A1510.
78. Gangavalli R, McCallister T, Jolly DJ, et al:Retroviral vector mediated cytokine gene transfer into human tumor cells for cancer therapy. Proc Annu Meet Am Assoc Cancer Res 1994;35:A1493.
79. Townsend SE, Allison JP:Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
80. Fenton RT, Sznol M, Luster DG, et al:A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma NCI protocol T93-0191. BRMP protocol 9401. Hum Gene Ther 1995;6:87-106.